SILVER SPRING, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”) today announced a change of the Company’s name to Elutia Inc. The rebranding reflects the strategic focus to develop and commercialize proprietary drug-eluting biomatrix technology aimed at improving surgical outcomes. The name change becomes effective […]
Tag: Aziyo Biologics
Aziyo Biologics Announces Publication of a CanGaroo® Case Study Demonstrating Bioenvelope Benefits for Reoperative Procedures
SILVER SPRING, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today announced the publication of a case report highlighting results that demonstrate the potential benefits […]
Aziyo Biologics Reports Second Quarter 2023 Financial Results – Transformation Continues to Drug-Eluting Biomatrix Company
SILVER SPRING, Md., Aug. 14, 2023 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, today provided a business update and reported financial results for the second quarter ended June […]
Aziyo Biologics Presents Positive Clinical Data on CanGaroo® Biologic Envelope
Study Presented at Heart Rhythm Society Supports Wound-Healing Benefits in Patients Receiving Cardiac Implantable Electronic Devices SILVER SPRING, Md., May 19, 2023 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need […]
Aziyo Biologics Announces Record Annual Net Sales in Preliminary (Unaudited) Fourth Quarter and Full Year 2022 Topline Results
SILVER SPRING, Md., Jan. 09, 2023 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today announced preliminary (unaudited) net sales results for its fourth quarter and full year […]
Aziyo Biologics Announces Funding of Additional $4 Million Term Loan with SWK Holdings Corporation
Follows recent equity financing, resulting in debt and equity gross proceeds of $15.2 million SILVER SPRING, Md., Dec. 15, 2022 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, […]
Aziyo Biologics Reports Strong Third Quarter 2022 Revenue
Positive meeting with FDA provides clarity for CanGaroo® RM clearance SILVER SPRING, Md., Nov. 14, 2022 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO), a biologics company with a portfolio of regenerative products aimed at improving compatibility between medical devices and the patients they treat, today provided a business update and […]
Aziyo Biologics Strengthens Leadership Team and Organizes for Growth in Key Markets
Senior team enhanced to advance Aziyo’s commercial and financial objectives SILVER SPRING, Md., Oct. 11, 2022 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO), a biological device company with a portfolio of commercial products across four distinct businesses, today announced key promotions and new hires that solidify its position as […]
Aziyo Biologics Announces $25 Million Loan Facility with SWK Holdings
Provides Additional Working Capital to Further Fund Growth Initiatives SILVER SPRING, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO) (the “Company”), a commercial-stage regenerative medicine company announced today that it has entered into a $25 million credit facility from SWK Holdings Corporation. The new credit facility […]
Aziyo Biologics Appoints Dr. C. Randal Mills as Interim President and CEO
SILVER SPRING, Md., June 21, 2022 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced Aziyo co-founder C. Randal (Randy) Mills, Ph.D., has been appointed interim president and […]
Recent
Popular
- No commented posts yet